Source: FierceHealthcare With new competitors closing in, UnitedHealth is bolstering its defenses by purchasing Genoa Healthcare, the fifth-largest pharmacy chain…...
Latest News

Alexion snaps up another biotech, paying $1.2B for Syntimmune
Source: FierceBiotech Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare…...

DOJ clears Cigna’s planned acquisition of Express Scripts
Source: FierceHealthcare The Department of Justice has given the green light to insurance giant Cigna Corp.'s planned $67 billion acquisition of pharmacy…...

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline
Source: Allergan DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed…...

Cigna, Express Scripts shareholders approve $67B deal
Source: FierceHealthcare Shareholders with both Cigna and Express Scripts voted to approve the insurer’s $67 billion acquisition of the PBM,…...

"You are simply the best at what you do. What a powerful resource and great business partner." - Director, U.S.…...

Allergan preludes major selloffs with $650M Almirall dermatology sale
Source: FiercePharma Allergan, which is shopping assets to help turn its stock price around, has taken its first small step…...

Bayer sells prescription dermatology brands to Denmark’s Leo Pharma
Source: Reuters FRANKFURT (Reuters) - Bayer has agreed to sell its established prescription dermatology brands to Denmark’s Leo Pharma, as…...

Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study Of SNA-120 In Patients With Itch Associated With Psoriasis
Source: Sienna Biopharmaceuticals Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b…...

Dermavant inks $330M deal for GSK’s phase 3-ready psoriasis drug
Source: FierceBiotech A new CSO isn't all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British…...